Damora Therapeutics Common Stock Sale Planned by Lori Firmani

Lori Firmani filed a notice to sell up to 1,800 shares of DMRA common stock through Maxim Group on the NASDAQ, with an aggregate value of $55,980.00 and an anticipated sale date of 08/05/2026.

Rhea-AI Filing Summary

Lori Firmani filed a notice to sell up to 1,800 shares of DMRA common stock through Maxim Group on the NASDAQ, with an aggregate value of $55,980.00 and an anticipated sale date of 08/05/2026. The shares relate to options dated 01/04/2023 issued by the company and are to be sold for cash.

The filing also lists DMRA common stock sales during the prior three months: 7,615 shares sold on 06/22/2026 for $192,882.00 and 242 shares sold on 05/19/2026 for $5,915.00.

Key Figures

Planned shares to be sold: 1,800 shares Planned aggregate sale value: $55,980.00 Sale venue: NASDAQ +5 more

8 metrics

Planned shares to be sold 1,800 shares Common stock to be sold through Maxim Group with anticipated date 08/05/2026

Planned aggregate sale value $55,980.00 Aggregate value for 1,800 DMRA common shares listed in the planned sale

Sale venue NASDAQ Exchange listed for the planned common stock sale through Maxim Group

Prior sale 1 7,615 shares for $192,882.00 DMRA common stock sold on 06/22/2026 by Lori Firmani

Prior sale 2 242 shares for $5,915.00 DMRA common stock sold on 05/19/2026 by Lori Firmani

Option grant date 01/04/2023 Date of the option from which the common stock to be sold originates

CUSIP-like identifier 61533194 Numeric identifier listed with the issuer’s common stock

Planned sale date 08/05/2026 Date associated with the proposed sale of 1,800 common shares

Key Terms

Common Stock, Option, NASDAQ

3 terms

Common Stock financial

"Common Stock | Maxim Group 300 Park Ave 16th Floor New York NY 10022"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Option financial

"Common Stock | 01/04/2023 | Option | Issuer |"

An option is a financial contract that gives its holder the right, but not the obligation, to buy or sell a stock at a specified price within a set time. Investors use options like a reservation or coupon to lock in a price, protect against losses, or amplify potential gains with a smaller upfront cost than owning the stock outright, making them useful for hedging, income strategies, or speculative bets.

NASDAQ market

"61533194 | 08/05/2026 | NASDAQ"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does DMRA’s recent Form 144 filing by Lori Firmani disclose?

The filing discloses a planned sale of 1,800 DMRA common shares through Maxim Group with an aggregate value of $55,980.00. It also reports prior three‑month sales totaling 7,857 shares on specified 2026 dates.

How many DMRA shares does Lori Firmani plan to sell under this notice?

The notice covers up to 1,800 shares of DMRA common stock. These shares are expected to be sold through Maxim Group on the NASDAQ, with an aggregate sale value stated as $55,980.00 in the filing.

What prior DMRA stock sales by Lori Firmani are reported in the Form 144?

The filing lists 7,615 shares of DMRA common stock sold on 06/22/2026 for $192,882.00 and 242 shares sold on 05/19/2026 for $5,915.00, summarizing activity in the previous three months.

What is the role of Maxim Group in the DMRA Form 144 filing?

Maxim Group is identified as the broker handling the planned sale of 1,800 DMRA shares. The filing lists its New York address and indicates the stock will be sold for cash on the NASDAQ market.

What is the planned sale date for the 1,800 DMRA shares in this Form 144?

The anticipated sale date for the 1,800 DMRA shares is 08/05/2026. This date appears next to the proposed sale information, indicating when the brokered NASDAQ transactions are expected to occur.

Are the DMRA shares in the planned sale related to stock options?

Yes. The filing links the common stock to an Option dated 01/04/2023 issued by the company. It specifies that the shares associated with this option are to be sold for cash by the listed broker.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/06/2026 - 11:35 AM Accepted by SEC EDGAR 08/06/2026 - 11:34 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001808248
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Damora Therapeutics, Inc.
SEC File Number	001-39655
Address of Issuer	221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MASSACHUSETTS 02453
Phone	(781) 281-9020
Name of Person for Whose Account the Securities are To Be Sold	Firmani Lori
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Maxim Group 300 Park Ave 16th Floor New York NY 10022	1800	55980.00	61533194	08/05/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/04/2023	Option	Issuer			703	08/05/2026	CASH
Common Stock	01/04/2023	Option	Issuer			1097	08/05/2026	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
LORI FIRMANI 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453	Common Stock	06/22/2026	7615	192882.00
LORI FIRMANI 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453	Common Stock	05/19/2026	242	5915.00

144: Remarks and Signature

Remarks
Date of Notice	08/06/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Dominick Iadicicco, as a duly authorized representative of Maxim Group LLC., as attorney-in-fact for Lori Firmani
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)